Best Oncology Companies in Philadelphia, United States
The 49 best Oncology companies in Philadelphia, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Century Therapeutics.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Philadelphia
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Century Therapeutics Developer of therapeutics for the treatment of autoimmune diseases and cancer 72Funding top 17%Growth top 30%Fin. health top 34%Market top 40% All 8 signals ▾Fundingtop 17% Growthtop 30% Fin. healthtop 34% Markettop 40% Moattop 42% Techbottom 45% Globalbottom 39% Newsbottom 23% Funding: Raised $410M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Growth: Revenue +1557% YoY · 1 acquisition/expansion move in 24 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $410M | 7 mo ago | 94 94 → 118 (+26%) | — | DrupalPHPAmazon Web Services+20 | — | 1 award |
| 2 | Tmunity Therapeutics Leveraging the immunological potential of T cells to treat a wide range of diseases | $231M | 81 mo ago | 43 | — | — | — | — |
| 3 | Imvax Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity | $175M | 18 mo ago | 50 | David Andrews Co-Founder & Chief Medical Officer | WordPressMySQLPHP+23 | 21 patents Biodiffusion chambers for advanced cell culture and drug screening applications. | — |
| 4 | Prelude Therapeutics Developer of chromatin function targeting drugs for the treatment of cancer and rare diseases | $145M | 71 mo ago | 128 128 → 106 (-17%) | Kris Vaddi Founder & CEO | DrupalPHPAmazon Web Services+23 | 311 patents Small‑molecule inhibitors of kinases and epigenetic enzymes for oncology therapeutics. | — |
| 5 | Carisma Therapeutics Developer of chimeric antigen receptor macrophages for the treatment of cancer | $142M | 46 mo ago | 34 | Michael Klichinsky Co-Founder and Chief Scientific Officer | DrupalPHPZURB Foundation+22 | — | — |
| 6 | Context Therapeutics Developing T cell engaging bispecific antibody therapies for solid tumors | $131M | 27 mo ago | 7 | — | DrupalPHPZURB Foundation+23 | — | 2 job openings |
| 7 | Interius Biotherapeutics Developer of gene therapies for treating multiple diseases | $129M | 26 mo ago | 25 25 → 19 (-24%) | — | — | 101 patents Engineered immune cell therapies and targeted gene delivery using mutant CSF1R and hepatocyte vectors | — |
| 8 | Adaptimmune Developer of novel cancer immunotherapies to treat cancer and infectious disease | $104M | 142 mo ago | 449 | Adrian Rawcliffe CEO | Apple iCloud MailMicrosoft 365Salesforce+17 | 2 patents Engineered T‑cell receptor therapies for targeted cancer immunotherapy | — |
| 9 | Fore Developer of therapies for cancer treatment | $81M | 15 mo ago | 41 | — | WordPressMySQLPHP+11 | — | — |
| 10 | Immunome Developer of antibody-based therapeutics for treating cancer | $54M | 63 mo ago | 37 | — | WordPressMySQLPHP+16 | 89 patents Antibody‑drug conjugates and chiral benzodiazepinone compounds for cancer therapy | — |
| 11 | Verismo Therapeutics Developer of CAR-T cell therapies for cancer 16Funding top 32%Moat top 39%Tech bottom 43%Global bottom 38% All 6 signals ▾Fundingtop 32% Moattop 39% Techbottom 43% Globalbottom 38% Marketbottom 25% Newsbottom 21% Funding: Raised $50.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 16/100 | $50M | 3 mo ago | 9 | — | WordPressMySQLPHP+18 | — | 1 job opening · 1 partnership · 1 award |
| 12 | Linnaeus Therapeutics Biotech developing small molecule therapies for cancer, guided by clinical experience | $16M | 5 mo ago | 5 | Christopher Natale Co-Founder | — | — | 2 awards |
| 13 | Avstera Developer of therapeutics for the treatment of cancer | $13M | 34 mo ago | 4 | Ajay Raju Co-Founder | — | — | — |
| 14 | Avammune Therapeutics Developer of small-molecule innate immune modulators for cancer therapy | $12M | 15 mo ago | — | Aditya Kulkarni Co-Founder & CSO | WebflowMicrosoft 365jsDelivr+6 | — | 1 job opening |
| 15 | Instadiagnostics Point-of-care diagnostics platform delivering rapid, comprehensive healthcare solutions | $11M | 14 mo ago | 5 | Johann deSa Founder | — | — | — |
| 16 | Vittoria Biotherapeutics Developer of T-cell therapies to address various medical conditions | $9M | 60 mo ago | 8 | Marco Ruella Co-Founder | — | 6 patents Engineering and manufacturing CD5-targeted CAR-T cells for immunotherapy | — |
| 17 | Greppo Technologies Developing minimally invasive surgical needle for cancer treatment | $8M | 81 mo ago | — | Mark Yim Founder | — | — | — |
| 18 | Oncoceutics Clinical-stage drug development company focused on oncology | $8M | 107 mo ago | 18 | — | — | 247 patents Small-molecule GPCR modulators (imipridones) for oncology therapeutics | — |
| 19 | Niiki Pharma Online Toto, Togel 4D & Slot platform with high winrates | $7M | 180 mo ago | 50 | Hooshmand Sheshbaradaran ex-Co-Fouder & CEO | — | — | — |
| 20 | LignaMed Developing breakthrough treatments for asthma, organ transplant viability, and fibrosis | $6M | 95 mo ago | 3 | — | — | 11 patents Stereospecific synthesis of secoisolariciresinol diglucoside enantiomers for nutraceuticals | — |
| 21 | UE LifeSciences Provider of a non-invasive breast cancer scanning device | $5M | 56 mo ago | 44 44 → 64 (+45%) | Bhaumik Sanghvi Co-Founder & COO | Cart FunctionalityStrikinglyNginx+18 | 65 patents Capacitive tactile sensors for non‑invasive tissue property measurement and lesion mapping | — |
| 22 | Quantason Develops bi-modal S/IDUS™ platform technology for diagnostic imaging and active screening | $5M | 165 mo ago | 11 | Edmond Rambod Co-Founder | — | 3 patents Ultrasound-based detection and localization of breast microcalcifications using phase and coded excitation | — |
| 23 | Rosetta Genomics MicroRNA-based molecular diagnostics, research laboratory, and testing services for cancer | $4M | 109 mo ago | 86 | — | — | 28 patents MicroRNA therapeutics targeting liver cancer diagnostics and treatment | — |
| 24 | Oncora AI-based clinical data analysis and decision support tool for oncologists | $3M | 106 mo ago | 9 | David Lindsay Co-Founder & CEO | — | — | — |
| 25 | CellVax Therapeutics Developer of cell-based cancer immunotherapy | $2M | 22 mo ago | 8 | Fernando Kreutz CEO | — | — | — |
| 26 | Chimeron Developer of nucleic acid-based therapeutic solutions for treating cancer | $2M | 28 mo ago | 12 | — | WordPressMySQLPHP+23 | — | — |
| 27 | Pinpoint Therapeutics Developer of therapeutics for cancer | $1M | 80 mo ago | — | Ravi Amaravadi Co-Founder | — | — | — |
| 28 | Alteris Therapeutics US-based biotech developing cancer therapeutic vaccine, acquired by Celldex in 2005 | $900K | — | — | Donald O'Rourke Co-Founder | — | — | — |
| 29 | Lenima Field Diagnostics Provider of point-of-care molecular diagnostics tests for infectious disease and cancer | $552K | 75 mo ago | 3 | Wan Shih Co-Founder | — | — | — |
| 30 | Longevity Biotech Developer of peptide-based drug candidates for a wide range of diseases | $520K | 76 mo ago | 5 | — | WordPressMySQLPHP+15 | — | — |
| 31 | Trevarx Biomedical Developer of radiopharmaceutical platforms for the treatment of cancer | $500K | 12 mo ago | 2 | — | — | — | — |
| 32 | Gladius Therapeutics Developer of therapeutics for cancer treatment | $300K | 35 mo ago | — | Michael Seiden Co-Founder & CEO | — | — | — |
| 33 | Hula Therapeutics Developer of therapeutics for cancer treatment | $250K | 24 mo ago | — | Matt Kremer Co-Founder | — | — | — |
Top 12 Oncology companies in Philadelphia
#1
Public · Philadelphia, Pennsylvania · founded 2018 · 94 employees$410Mraised▾
Developer of therapeutics for the treatment of autoimmune diseases and cancer. The company's iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.
- Jan 2026Post IPO$135M
- Apr 2024Post IPO$60M
- Mar 2021Series C$160M
- Jul 2019Series C$250M
#2
Series A · Philadelphia, Pennsylvania · founded 2020 · 9 employees$50Mraised▾
Developer of CAR-T cell therapies for cancer. The KIR-CAR cell therapy provides stimulation to the cell that enhances the T-cell activation and elimination of antigen-negative tumor cells. It provides a product SynKIR-meso for pancreatic cancer, ovarian cancer, and mesothelioma.
- Apr 2026Series A$28M
- Jul 2023Seed$19.2M
- Feb 2023Seed$7M
- Apr 2021Seed$16M
#3
Series B · Philadelphia, Pennsylvania · founded 2018 · 5 employees$15.8Mraised▾
Biotech developing small molecule therapies for cancer, guided by clinical experience. The company identifies and develops innovative treatments for various cancers by listening to and learning from clinical experiences. This approach leads to the identification of new therapeutic targets. They focus on translating clinical insights into effective therapies, with a commitment to advancing drug candidates into human trials safely and quickly. Their team possesses diverse skills and expertise to drive the development of transformative cancer treatments. They are dedicated to improving patient outcomes through innovative science and a deep understanding of the clinical landscape. The company is focused on small molecule agents, clinical experience, therapeutic targets, and cancer treatment.
- Feb 2026Series B$5M
- Aug 2025Series B$1.3M
- Jan 2025Grant (prize money)$1000K
- Aug 2024Series B$5.8M
#4
Series C · Philadelphia, Pennsylvania · founded 2015 · 50 employees$174.8Mraised▾
Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity. This biopharmaceutical company is dedicated to turning the complexity of solid tumors against themselves through personalized, whole tumor-derived immunotherapies. Their unique platform captures a tumor’s full antigen signature and uses it to stimulate the patient’s innate and adaptive immunity against remaining tumor cells. They are developing a diverse pipeline of personalized treatments with promising clinical data in Glioblastoma and preclinical data in multiple other solid tumors. The company focuses on research & development strategy and activities, clinical development, and potential product development to deliver therapies targeting solid tumors. They are committed to innovation in the field of personalized immunotherapy.
- Jan 2025Series C$29M
- Sep 2023Series C$23M
- Jul 2020Series C$112.4M
- May 2019Series B$24.8M
#5
Series D · Philadelphia, Pennsylvania · founded 2011 · 41 employees$81Mraised▾
Developer of therapies for cancer treatment. The company's lead candidate FORE8394 is a small-molecule, next-generation, orally available selective inhibitor of mutated BRA for the treatment of tumors.
- Apr 2025Series D$38M
- Aug 2023Series D$75M
- Apr 2018Series A$6M
#6
Funding Raised · Philadelphia, Pennsylvania · founded 2015 · 5 employees$11Mraised▾
Point-of-care diagnostics platform delivering rapid, comprehensive healthcare solutions. The company provides a diagnostic technology platform designed to empower healthcare professionals with the capability to perform various tests directly at their clinics. This innovative system utilizes a portable, multi-modality reader and application-specific cartridges to deliver timely, accurate, and comprehensive healthcare within a single visit. The platform supports immunoassay, chemistry, and molecular assays, as well as complete blood cell counts. The fully automated system minimizes user errors and provides rapid results, enhancing efficiency and improving patient outcomes. This technology offers a single device solution, reducing the need for multiple systems and extensive training. The platform features wireless connectivity and electronic medical record compatibility, facilitating seamless integration into existing healthcare workflows. This is a B2B tech company in the healthcare industry.
- May 2025Grant (prize money)$4.1M
- Sep 2021Grant (prize money)$1M
- Jul 2020Grant (prize money)$4.1M
- Feb 2020Grant (prize money)$225K
#7
Series A · Philadelphia, Pennsylvania · founded 2019$12Mraised▾
Developer of small-molecule innate immune modulators for cancer therapy. It discovers and develops orally available drug candidates that target enzymes and pathways in the innate immune system to treat solid tumors and autoimmune diseases. Its pipeline includes AVA-NP-695 which is ENPP inhibitors and AVA-ADR-001 ADAR inhibitors designed to provide antitumor activity and synergy with checkpoint inhibitors and radiation.
- May 2025Series A$12M
- Jul 2022Series A—
- Mar 2022Series A—
- Jul 2019Series A—
#8
Acquired · Philadelphia, Pennsylvania · founded 2020 · 25 employees$129Mraised▾
Developer of gene therapies for treating multiple diseases. It is developing cell therapy by using lentiviral pseudotyping that enhances the efficiency of gene therapy. It transforms cells through the in-vivo generation of therapeutic immune and blood cells including Chimeric Antigen Receptor T Cells (CAR-T) for cancers, regulatory T Cells (Treg) for autoimmune diseases, and CD34+ hematopoietic stem cells (HSC) for blood disorders.
- May 2024Series A$51.4M
- Oct 2023Conventional Debt$21.5M
- May 2021Series A$76M
- Mar 2020Seed$1.6M
#9
Public · Philadelphia, Pennsylvania · founded 2015 · 7 employees$131.2Mraised▾
Developing T cell engaging bispecific antibody therapies for solid tumors. The company is dedicated to advancing the next generation of T cell engaging (TCE) bispecific antibody therapies to treat solid tumors. It is building an innovative portfolio of clinical-stage TCE bispecific antibody therapeutics. The pipeline includes product candidates targeting Claudin 6, Mesothelin, and Nectin-4. The company's purpose is driven by a passion for helping patients with cancer and a belief that better treatments are possible. The focus is on innovation in the field of cancer therapeutics, specifically through the development of bispecific antibody technology. The company values inclusion, transparency, and accountability in its operations.
- May 2024Post IPO$100M
- Dec 2021Post IPO$31.2M
#10
Seed · Philadelphia, Pennsylvania · founded 2016 · 2 employees$500Kraised▾
Developer of radiopharmaceutical platforms for the treatment of cancer. The company's lead product is Fluorine-18 Fluorthanatrace which measures tumor expression of PARP-1 to treat breast cancer.
- Jul 2025Seed$350K
- Sep 2022Seed$500K
#11
Public · Philadelphia, Pennsylvania · founded 2016 · 34 employees$142Mraised▾
Developer of chimeric antigen receptor macrophages for the treatment of cancer. The company has genetically engineering patient macrophages to create chimeric antigen receptor macrophages (CARMA). The company is focussing on solid tumor indications including recurrent ovarian cancer and HER2-overexpressing malignancies.
- Sep 2022Post IPO$30M
- Jan 2021Post IPO$59M
- Jul 2019Post IPO$53M
- Apr 2017Post IPO$3.9M
#12
Acqui-Hired · Philadelphia, Pennsylvania · founded 2015 · 43 employees$231Mraised▾
Tmunity Therapeutics, co-founded by the University of Pennsylvania (Penn), the Perelman School of Medicine at Penn and the University of Pennsylvania Health System, is focused on leveraging the immunological potential of T cells to treat a wide range of diseases. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), universal engineered T cell platforms, and Chimeric Antigen Receptor (CAR) therapies to control T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease toward the clinic. In addition, Tmunity has secured its own manufacturing facility in Norristown, PA, that will enable process improvement and production scale-up to support future multi-center clinical studies across diverse therapeutic indications.
- Oct 2019Series B$75M
- Apr 2018Series A$35M
- Jan 2018Series A$100M
- Jan 2018Series A$5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology in Philadelphia is moving
A read on the academic research around Oncology in Philadelphia — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 87 papers.
- Children\'s Hospital of Philadelphia56
- Philadelphia University30
- Philadelphia VA Medical Center3
- Philadelphia College of Osteopathic Medicine3
- Einstein Medical Center Philadelphia1
- Tumor microenvironment1→20
- Cancer research2→16
- Immunotherapy1→12
- Tumor microenvironment1→11
- Immune system1→10
- Cancer1→6
- Tumor microenvironment5
- Chimeric antigen receptor3
- Immune system3
- T cell2
- Cancer research2
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.